Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004229786> ?p ?o ?g. }
- W2004229786 endingPage "118" @default.
- W2004229786 startingPage "112" @default.
- W2004229786 abstract "Purpose To review the impact of high–dose radiotherapy (RT) in the postprostatectomy salvage setting on long-term biochemical control and distant metastases–free survival, and to identify clinical and pathologic predictors of outcomes. Methods and Materials During 1988–2007, 285 consecutive patients were treated with salvage RT (SRT) after radical prostatectomy. All patients were treated with either three-dimensional conformal RT or intensity-modulated RT. Two hundred seventy patients (95%) were treated to a dose ≥66 Gy, of whom 205 (72%) received doses ≥70 Gy. Eighty-seven patients (31%) received androgen-deprivation therapy as a component of their salvage treatment. All clinical and pathologic records were reviewed to identify treatment risk factors and response. Results The median follow-up time after SRT was 60 months. Seven-year actuarial prostate-specific antigen (PSA) relapse-free survival and distant metastases–free survival were 37% and 77%, respectively. Independent predictors of biochemical recurrence were vascular invasion (p < 0.01), negative surgical margins (p < 0.01), presalvage PSA level >0.4 ng/mL (p < 0.01), androgen-deprivation therapy (p = 0.03), Gleason score ≥7 (p = 0.02), and seminal vesicle involvement (p = 0.05). Salvage RT dose ≥70 Gy was not associated with improvement in biochemical control. A doubling time <3 months was the only independent predictor of metastatic disease (p < 0.01). There was a trend suggesting benefit of SRT dose ≥70 Gy in preventing clinical local failure in patients with radiographically visible local disease at time of SRT (7 years: 90% vs. 79.1%, p = 0.07). Conclusion Salvage RT provides effective long-term biochemical control and freedom from metastasis in selected patients presenting with detectable PSA after prostatectomy. Androgen-deprivation therapy was associated with improvement in biochemical progression-free survival. Clinical local failures were rare but occurred most commonly in patients with greater burden of disease at time of SRT as reflected by either radiographic imaging or a greater PSA level. Salvage radiation doses ≥70 Gy may ultimately be most beneficial in these patients, but this needs to be further studied. To review the impact of high–dose radiotherapy (RT) in the postprostatectomy salvage setting on long-term biochemical control and distant metastases–free survival, and to identify clinical and pathologic predictors of outcomes. During 1988–2007, 285 consecutive patients were treated with salvage RT (SRT) after radical prostatectomy. All patients were treated with either three-dimensional conformal RT or intensity-modulated RT. Two hundred seventy patients (95%) were treated to a dose ≥66 Gy, of whom 205 (72%) received doses ≥70 Gy. Eighty-seven patients (31%) received androgen-deprivation therapy as a component of their salvage treatment. All clinical and pathologic records were reviewed to identify treatment risk factors and response. The median follow-up time after SRT was 60 months. Seven-year actuarial prostate-specific antigen (PSA) relapse-free survival and distant metastases–free survival were 37% and 77%, respectively. Independent predictors of biochemical recurrence were vascular invasion (p < 0.01), negative surgical margins (p < 0.01), presalvage PSA level >0.4 ng/mL (p < 0.01), androgen-deprivation therapy (p = 0.03), Gleason score ≥7 (p = 0.02), and seminal vesicle involvement (p = 0.05). Salvage RT dose ≥70 Gy was not associated with improvement in biochemical control. A doubling time <3 months was the only independent predictor of metastatic disease (p < 0.01). There was a trend suggesting benefit of SRT dose ≥70 Gy in preventing clinical local failure in patients with radiographically visible local disease at time of SRT (7 years: 90% vs. 79.1%, p = 0.07). Salvage RT provides effective long-term biochemical control and freedom from metastasis in selected patients presenting with detectable PSA after prostatectomy. Androgen-deprivation therapy was associated with improvement in biochemical progression-free survival. Clinical local failures were rare but occurred most commonly in patients with greater burden of disease at time of SRT as reflected by either radiographic imaging or a greater PSA level. Salvage radiation doses ≥70 Gy may ultimately be most beneficial in these patients, but this needs to be further studied." @default.
- W2004229786 created "2016-06-24" @default.
- W2004229786 creator A5012224683 @default.
- W2004229786 creator A5018824031 @default.
- W2004229786 creator A5028303511 @default.
- W2004229786 creator A5030594142 @default.
- W2004229786 creator A5046270690 @default.
- W2004229786 creator A5049069950 @default.
- W2004229786 creator A5077778024 @default.
- W2004229786 creator A5080654647 @default.
- W2004229786 creator A5081611907 @default.
- W2004229786 date "2012-09-01" @default.
- W2004229786 modified "2023-09-23" @default.
- W2004229786 title "Long-Term Outcomes After High-Dose Postprostatectomy Salvage Radiation Treatment" @default.
- W2004229786 cites W195279437 @default.
- W2004229786 cites W1996809772 @default.
- W2004229786 cites W2040659915 @default.
- W2004229786 cites W2052766723 @default.
- W2004229786 cites W2053690746 @default.
- W2004229786 cites W2054899405 @default.
- W2004229786 cites W2061899677 @default.
- W2004229786 cites W2070615987 @default.
- W2004229786 cites W2071879495 @default.
- W2004229786 cites W2096600898 @default.
- W2004229786 cites W2101889062 @default.
- W2004229786 cites W2103429819 @default.
- W2004229786 cites W2105684279 @default.
- W2004229786 cites W2126428795 @default.
- W2004229786 cites W2137491531 @default.
- W2004229786 cites W2140754632 @default.
- W2004229786 cites W2149806448 @default.
- W2004229786 cites W2151674154 @default.
- W2004229786 cites W2152525304 @default.
- W2004229786 cites W2159790321 @default.
- W2004229786 doi "https://doi.org/10.1016/j.ijrobp.2011.10.077" @default.
- W2004229786 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22300563" @default.
- W2004229786 hasPublicationYear "2012" @default.
- W2004229786 type Work @default.
- W2004229786 sameAs 2004229786 @default.
- W2004229786 citedByCount "79" @default.
- W2004229786 countsByYear W20042297862013 @default.
- W2004229786 countsByYear W20042297862014 @default.
- W2004229786 countsByYear W20042297862015 @default.
- W2004229786 countsByYear W20042297862016 @default.
- W2004229786 countsByYear W20042297862017 @default.
- W2004229786 countsByYear W20042297862018 @default.
- W2004229786 countsByYear W20042297862019 @default.
- W2004229786 countsByYear W20042297862020 @default.
- W2004229786 countsByYear W20042297862021 @default.
- W2004229786 countsByYear W20042297862022 @default.
- W2004229786 crossrefType "journal-article" @default.
- W2004229786 hasAuthorship W2004229786A5012224683 @default.
- W2004229786 hasAuthorship W2004229786A5018824031 @default.
- W2004229786 hasAuthorship W2004229786A5028303511 @default.
- W2004229786 hasAuthorship W2004229786A5030594142 @default.
- W2004229786 hasAuthorship W2004229786A5046270690 @default.
- W2004229786 hasAuthorship W2004229786A5049069950 @default.
- W2004229786 hasAuthorship W2004229786A5077778024 @default.
- W2004229786 hasAuthorship W2004229786A5080654647 @default.
- W2004229786 hasAuthorship W2004229786A5081611907 @default.
- W2004229786 hasConcept C121608353 @default.
- W2004229786 hasConcept C126322002 @default.
- W2004229786 hasConcept C126894567 @default.
- W2004229786 hasConcept C141071460 @default.
- W2004229786 hasConcept C2776694085 @default.
- W2004229786 hasConcept C2777008409 @default.
- W2004229786 hasConcept C2777899217 @default.
- W2004229786 hasConcept C2779466945 @default.
- W2004229786 hasConcept C2780192828 @default.
- W2004229786 hasConcept C2780775027 @default.
- W2004229786 hasConcept C2781406297 @default.
- W2004229786 hasConcept C509974204 @default.
- W2004229786 hasConcept C71924100 @default.
- W2004229786 hasConceptScore W2004229786C121608353 @default.
- W2004229786 hasConceptScore W2004229786C126322002 @default.
- W2004229786 hasConceptScore W2004229786C126894567 @default.
- W2004229786 hasConceptScore W2004229786C141071460 @default.
- W2004229786 hasConceptScore W2004229786C2776694085 @default.
- W2004229786 hasConceptScore W2004229786C2777008409 @default.
- W2004229786 hasConceptScore W2004229786C2777899217 @default.
- W2004229786 hasConceptScore W2004229786C2779466945 @default.
- W2004229786 hasConceptScore W2004229786C2780192828 @default.
- W2004229786 hasConceptScore W2004229786C2780775027 @default.
- W2004229786 hasConceptScore W2004229786C2781406297 @default.
- W2004229786 hasConceptScore W2004229786C509974204 @default.
- W2004229786 hasConceptScore W2004229786C71924100 @default.
- W2004229786 hasIssue "1" @default.
- W2004229786 hasLocation W20042297861 @default.
- W2004229786 hasLocation W20042297862 @default.
- W2004229786 hasOpenAccess W2004229786 @default.
- W2004229786 hasPrimaryLocation W20042297861 @default.
- W2004229786 hasRelatedWork W1606338785 @default.
- W2004229786 hasRelatedWork W1967410728 @default.
- W2004229786 hasRelatedWork W197525946 @default.
- W2004229786 hasRelatedWork W2026113581 @default.
- W2004229786 hasRelatedWork W2156750644 @default.
- W2004229786 hasRelatedWork W2329894078 @default.
- W2004229786 hasRelatedWork W2402249956 @default.